Risk stratification of severe infections after remission induction therapy in idiopathic inflammatory myopathy: a multicentre MYKO study
- 28 October 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Abstract
Objectives: To identify baseline predictors and develop a clinical risk stratification model for severe infections (SIs) in patients with idiopathic inflammatory myopathy (IIM) after remission induction therapy. Methods: We enrolled patients diagnosed with IIM between 1991 and 2024 from three Japanese centres participating in the multicentre Idiopathic Inflammatory Myopathy and Anti-synthetase Syndrome (MYKO) cohort. SI was defined as an infection requiring i.v. antibiotics or hospitalization. We explored the risk factors for predicting SI in patients with IIM by comparing the initial demographic, clinical, laboratory and treatments between the SI and non-SI groups. Results: Among 349 patients with IIM, 14.6% of patients developed SIs after remission induction therapy over a median follow-up of 4.7 years. Patients who developed SI exhibited significantly lower baseline albumin levels, and significantly higher baseline CRP, lactate dehydrogenase and surfactant protein (SP-D) levels than those without SI. Multivariate logistic regression analysis demonstrated that elevated CRP and SP-D levels were independently associated with SI. Serum CRP levels remained significantly higher in the SI group than in the non-SI group over the 2-year period after immunosuppressive therapy, and the serum SP-D levels tended to be higher in the SI group. The 10-year SI rate was significantly different among patients with IIM stratified by the number of risk factors, defined as CRP ≥ 0.8 mg/dl and SP-D ≥ 96.2 ng/ml. Conclusions: This model, which consists of CRP ≥ 0.8 mg/dl, SP-D ≥ 96.2 ng/ml, is useful for clinical risk stratification of SI after remission induction therapy in IIM.Keywords
This publication has 47 references indexed in Scilit:
- Long-term outcomes of idiopathic inflammatory myopathies: a large-scale longitudinal cohort studyJournal of Autoimmunity, 2025
- A nomogram for the prediction of co-infection in MDA5 dermatomyositis: A rapid clinical assessment modelClinical Immunology, 2025
- Long‐Term Outcomes and Prognosis Factors in Patients With Idiopathic Inflammatory Myopathies Based on Myositis‐Specific Autoantibodies: A Single Cohort StudyArthritis Care & Research, 2022
- Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositisCytokine, 2019
- Classification of myositisNature Reviews Rheumatology, 2018
- Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of SpainRheumatology International, 2017
- Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 PatientsSeminars in Arthritis and Rheumatism, 2011
- A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): A missing link within the spectrum of the idiopathic inflammatory myopathiesJournal of the American Academy of Dermatology, 2006
- Opportunistic infections in polymyositis and dermatomyositisArthritis Care & Research, 2005
- Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspectsDermatologic Clinics, 2002